We can't find the internet
Attempting to reconnect
Something went wrong
Hang in there while we get back on track
£795.00
It has never been this cheap. We have no record of a lower price.
£795 today · cheaper than every other day in the last 3 months
The 2023-2028 World Outlook for Acute-Treatment Migraine Drugs
We'll watch every seller, every day. One email when your price arrives.
Price History & Forecast
Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.
Last 89 days · 89 data points
Historical
Generating forecast…
NEW HERE?
Amazon shows you one price. We show you all of them.
Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.
WHAT'S ON THIS PAGE
↑ Price chart
when this has been cheap or pricey
when this has been cheap or pricey
↑ Forecast
where the price is heading next
where the price is heading next
↓ Statistics
all-time high & low, recent range
all-time high & low, recent range
↑ Price alert
name your number, we'll email you
name your number, we'll email you
Price Distribution
Price distribution over 89 days • 1 price levels
Price Analysis
Most common price: £795 (89 days, 100.0%)
Price range: £795 - £795
Price levels: 1 different prices over 89 days
Description
This study covers the world outlook for acute-treatment migraine drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of acute-treatment migraine drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Allergan, Amgen, Biohaven Pharmaceutical Holding Company, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
Product Specifications
- Format
- paperback
- ASIN
- B09WCPWKHX
- Category
- Books > Subjects
- Domain
- Amazon UK
- Release Date
- 30 June 2022
- Listed Since
- 14 April 2022
Similar Products You Might Like
99% match
The 2021-2026 World Outlook for Anti-Migraine Drugs
£795.00
24 Aug 2026
99% match
US Anti-Migraine Drug Market Outlook 2023-2028 Study
£520.00
07 Nov 2026
99% match
Anti-Migraine Drugs in India Outlook 2023-2028 Study
£515.00
09 Nov 2026
99% match
The 2023-2028 Outlook for Anti-Migraine Drugs in China
£495.00
04 Nov 2026
99% match
The 2023-2028 Outlook for Anti-Migraine Drugs in Japan
£495.00
29 Oct 2026
99% match
2025-2030 World Outlook for Anti-Migraine Drugs Study
Price unavailable
98% match
Anti-Migraine Drug Outlook in Greater China 2016-2021
£595.00
25 Aug 2026
98% match
Anti-Migraine Drugs in Europe Outlook 2016-2021 Report
£425.00
09 Nov 2026
98% match
US Anti-Migraine Drug Market Outlook 2016-2021 Study
£595.00
06 Nov 2026
98% match
Anti-Migraine Drug Outlook in Asia 2016-2021 Study
£425.00
06 Nov 2026
98% match
Anti-Migraine Drug Outlook Latin America 2016-2021 Study
£425.00
07 Nov 2026
98% match
The 2013-2018 Outlook for Anti-Migraine Drugs in Europe & the Middle East
£325.00
05 Nov 2026
98% match
The 2016-2021 Outlook for Anti-Migraine Drugs in India
£595.00
03 Nov 2026
98% match
The 2013-2018 Outlook for Anti-Migraine Drugs in Africa
£325.00
31 Oct 2026
98% match
Anti-Migraine Drug Outlook North America & Caribbean Study
£425.00
05 Nov 2026
98% match
The 2016 Report on Anti-Migraine Drugs: World Market Segmentation by City
£995.00
28 Oct 2026
98% match
Anti-Migraine Drug Outlook in Oceana 2016-2021 Study
£425.00
26 Sep 2026
98% match
Anti-Migraine Drug Outlook: Africa & Middle East Study
£425.00
05 Nov 2026
98% match
US Anti-Migraine Drug Outlook 2023-2028 - Zip Code Study
£490.00
04 Sep 2026
98% match
Anti-Migraine Drug Outlook in Middle East (2011-2016)
£325.00
24 Aug 2026
97% match
Traitements de crise et traitements de fond de la migraine: Aspects pharmacothérapeutiques (Omn.Univ.Europ.)
OmniScriptum
£70.00
30 Sep 2026
97% match
Migraine and Headache Disorders: Global Perspective - SDG3
Springer
£95.74
25 Sep 2026
97% match
Interventional Management of Migraines and Headache Disorders Book
Elsevier
£119.49
02 Oct 2026
97% match
Management of Migraine Pain: Emerging Opportunities and Challenges
Springer
£162.90
02 Oct 2026